<p>LB Pharmaceuticals Inc（納斯達克：LBRX - 獲取免費報告）在週二的交易中達到了新的 52 周高點。該公司的股價最高達到 32.49 美元，最後交易價格為 31.67 美元，成交量為 208549 股。該股票此前收盤價為 30.52 美元。</p>
<p>獲取 <strong>LB Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>多家研究分析師最近對該股票發佈了報告。Stifel Nicolaus 將 LB Pharmaceuticals 的股票目標價從 35.00 美元上調至 40.00 美元，並在 3 月 27 日的研究報告中給予該股票 “買入” 評級。Craig Hallum 在 4 月 10 日的研究報告中開始覆蓋 LB Pharmaceuticals 的股票。他們給予該股票 “買入” 評級和 36.00 美元的目標價。Roth Mkm 在 1 月 9 日的研究報告中開始覆蓋 LB Pharmaceuticals 的股票。他們給予該股票 “買入” 評級和 31.00 美元的目標價。最後，Weiss Ratings 在 12 月 29 日的研究報告中重申了對 LB Pharmaceuticals 的 “賣出（e）” 評級。一位研究分析師給予該股票 “強烈買入” 評級，四位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，LB Pharmaceuticals 的共識評級為 “適度買入”，平均目標價為 35.25 美元。</p>
<p><strong>獲取我們對 LBRX 的最新分析</strong></p>
<h2>LB Pharmaceuticals 股價上漲 3.8%</h2>
<p>該股票的 50 日移動平均價格為 24.94 美元，200 日移動平均價格為 20.95 美元。該公司的市值為 9.0798 億美元，市盈率為-29.88。</p>
<p>LB Pharmaceuticals（納斯達克：LBRX - 獲取免費報告）最近在 3 月 26 日發佈了季度財報。該公司報告每股收益（EPS）為-0.45 美元，符合分析師的共識預期（-0.45 美元）。賣方分析師預計 LB Pharmaceuticals Inc 在當前財年將發佈-3.85 美元的每股收益。</p>
<h2>LB Pharmaceuticals 的機構交易</h2>
<p>多家大型投資者最近調整了對 LBRX 的持股。加利福尼亞州教師退休系統在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 26,000 美元。美國銀行在第三季度新購入了 LB Pharmaceuticals 的股份，價值約 27,000 美元。拉塞爾投資集團在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 34,000 美元。Strs Ohio 在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 76,000 美元。最後，Persistent Asset Partners Ltd 在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 91,000 美元。</p>
<h2>LB Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>我們是一家臨牀階段的生物製藥公司，開發用於治療精神分裂症、雙相抑鬱症和其他神經精神疾病的新療法。我們正在建立一個利用我們主要產品候選藥物 LB-102 廣泛治療潛力的產品線，我們相信該藥物有潛力成為美國首個獲批用於神經精神疾病的苯酰胺類抗精神病藥物。LB-102 是一種新化合物，是阿米舒利普的甲基化衍生物，阿米舒利普是一種在超過 50 個國家獲批的第二代抗精神病藥物，但不包括美國，因為美國的開發和監管要求。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過 LB Pharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 LB Pharmaceuticals 嗎？</h2>
<p>在你考慮 LB Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 LB Pharmaceuticals 並不在名單上。</p>
<p>雖然 LB Pharmaceuticals 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LBRX

<p>LB Pharmaceuticals（納斯達克代碼：LBRX）在交易中達到了新的 52 周高點 32.49 美元，收盤價為 31.67 美元。分析師們提高了目標價格，Stifel Nicolaus 將其目標價從 35.00 美元上調至 40.00 美元，並維持 “買入” 評級。該股票的共識評級為 “適度買入”，平均目標價格為 35.25 美元。公司報告每股收益為（0.45 美元），符合預期。機構投資者最近增加了對 LB Pharmaceuticals 的持股，該公司專注於開發神經精神疾病的治療方案</p>

<p>LB Pharmaceuticals Inc (NASDAQ:LBRX - Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $32.49 and last traded at $31.67, with a volume of 208549 shares trading hands. The stock had previously closed at $30.52.</p>
<div class="lb-trans"><p>LB Pharmaceuticals Inc（納斯達克：LBRX - 獲取免費報告）在週二的交易中達到了新的 52 周高點。該公司的股價最高達到 32.49 美元，最後交易價格為 31.67 美元，成交量為 208549 股。該股票此前收盤價為 30.52 美元。</p>
</div><p>Get <strong>LB Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>LB Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of research analysts have recently issued reports on the stock. Stifel Nicolaus raised their price target on shares of LB Pharmaceuticals from $35.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 27th. Craig Hallum assumed coverage on shares of LB Pharmaceuticals in a research report on Friday, April 10th. They issued a &#34;buy&#34; rating and a $36.00 price target on the stock. Roth Mkm assumed coverage on shares of LB Pharmaceuticals in a research report on Friday, January 9th. They issued a &#34;buy&#34; rating and a $31.00 price target on the stock. Finally, Weiss Ratings restated a &#34;sell (e)&#34; rating on shares of LB Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, LB Pharmaceuticals has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $35.25.</p>
<div class="lb-trans"><p>多家研究分析師最近對該股票發佈了報告。Stifel Nicolaus 將 LB Pharmaceuticals 的股票目標價從 35.00 美元上調至 40.00 美元，並在 3 月 27 日的研究報告中給予該股票 “買入” 評級。Craig Hallum 在 4 月 10 日的研究報告中開始覆蓋 LB Pharmaceuticals 的股票。他們給予該股票 “買入” 評級和 36.00 美元的目標價。Roth Mkm 在 1 月 9 日的研究報告中開始覆蓋 LB Pharmaceuticals 的股票。他們給予該股票 “買入” 評級和 31.00 美元的目標價。最後，Weiss Ratings 在 12 月 29 日的研究報告中重申了對 LB Pharmaceuticals 的 “賣出（e）” 評級。一位研究分析師給予該股票 “強烈買入” 評級，四位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，LB Pharmaceuticals 的共識評級為 “適度買入”，平均目標價為 35.25 美元。</p>
</div><p><strong>Get Our Latest Analysis on LBRX</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 LBRX 的最新分析</strong></p>
</div><h2>LB Pharmaceuticals Trading Up 3.8%</h2>
<div class="lb-trans"><h2>LB Pharmaceuticals 股價上漲 3.8%</h2>
</div><p>The stock's 50-day moving average price is $24.94 and its 200-day moving average price is $20.95. The company has a market capitalization of $907.98 million and a P/E ratio of -29.88.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均價格為 24.94 美元，200 日移動平均價格為 20.95 美元。該公司的市值為 9.0798 億美元，市盈率為-29.88。</p>
</div><p>LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45). Sell-side analysts expect that LB Pharmaceuticals Inc will post -3.85 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>LB Pharmaceuticals（納斯達克：LBRX - 獲取免費報告）最近在 3 月 26 日發佈了季度財報。該公司報告每股收益（EPS）為-0.45 美元，符合分析師的共識預期（-0.45 美元）。賣方分析師預計 LB Pharmaceuticals Inc 在當前財年將發佈-3.85 美元的每股收益。</p>
</div><h2>Institutional Trading of LB Pharmaceuticals</h2>
<div class="lb-trans"><h2>LB Pharmaceuticals 的機構交易</h2>
</div><p>A number of large investors have recently modified their holdings of LBRX. California State Teachers Retirement System acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $26,000. Bank of America Corp DE acquired a new stake in shares of LB Pharmaceuticals in the 3rd quarter worth about $27,000. Russell Investments Group Ltd. acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $34,000. Strs Ohio acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $76,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter worth about $91,000.</p>
<div class="lb-trans"><p>多家大型投資者最近調整了對 LBRX 的持股。加利福尼亞州教師退休系統在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 26,000 美元。美國銀行在第三季度新購入了 LB Pharmaceuticals 的股份，價值約 27,000 美元。拉塞爾投資集團在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 34,000 美元。Strs Ohio 在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 76,000 美元。最後，Persistent Asset Partners Ltd 在第四季度新購入了 LB Pharmaceuticals 的股份，價值約 91,000 美元。</p>
</div><h2>LB Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>LB Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.</p>
<div class="lb-trans"><p>我們是一家臨牀階段的生物製藥公司，開發用於治療精神分裂症、雙相抑鬱症和其他神經精神疾病的新療法。我們正在建立一個利用我們主要產品候選藥物 LB-102 廣泛治療潛力的產品線，我們相信該藥物有潛力成為美國首個獲批用於神經精神疾病的苯酰胺類抗精神病藥物。LB-102 是一種新化合物，是阿米舒利普的甲基化衍生物，阿米舒利普是一種在超過 50 個國家獲批的第二代抗精神病藥物，但不包括美國，因為美國的開發和監管要求。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than LB Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 LB Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LB Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 LB Pharmaceuticals 嗎？</h2>
</div><p>Before you consider LB Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 LB Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LB Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 LB Pharmaceuticals 並不在名單上。</p>
</div><p>While LB Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 LB Pharmaceuticals 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High  - Time to Buy?

Market Beat

LB Pharmaceuticals

Stifel Financial

美國銀行

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

LB Pharmaceuticals（NASDAQ:LBRX）創下 52 周新高 - 現在是買入的好時機嗎？